Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Restenosis after Angioplasty.

Mehran Moussavian1, Peter J. Casterella, Paul S. Teirstein

  • 1Division of Interventional Cardiology, Scripps Clinic Medical Group, 10666 North Torrey Pines Road, SW-206, La Jolla, CA 92037, USA. pcasterella@scrippsclinic.com

Current Treatment Options in Cardiovascular Medicine
|March 10, 2001
PubMed
Summary

Coronary restenosis after angioplasty is common, but intracoronary stents reduce its occurrence. Brachytherapy effectively treats in-stent restenosis, with emerging therapies showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation.

The New England journal of medicine·2026
Same author

Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis.

The American journal of cardiology·2003
Same author

Pilot trial of oral rapamycin for recalcitrant restenosis.

Circulation·2003
See all related articles

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • Angiographic restenosis affects 30-50% of patients post-percutaneous transluminal coronary angioplasty (PTCA), leading to significant morbidity and healthcare costs.
  • Intracoronary stents are the primary treatment, reducing restenosis and target lesion revascularization (TLR) by 20-30% in appropriate lesions.
  • Restenosis remains a challenge, occurring in 15-25% of patients within 6 months of stent placement.

Purpose of the Study:

  • To review the current strategies for managing angiographic restenosis after PTCA.
  • To evaluate the efficacy of intracoronary stenting and adjunctive therapies.
  • To discuss emerging treatments for coronary restenosis.

Main Methods:

  • Review of existing literature on coronary restenosis and its management.

Related Experiment Videos

  • Analysis of the role of intracoronary stents in preventing and treating restenosis.
  • Evaluation of adjunctive therapies including brachytherapy and novel approaches.

    • Main Results:

    • Stenting is recommended for obstructive coronary lesions >3.0 mm and chronically occluded vessels, with benefits in smaller vessels being controversial.
    • Repeat PTCA is the initial approach for focal in-stent restenosis; debulking may be needed for diffuse restenosis.
    • Brachytherapy reduces recurrent in-stent restenosis by 40-70% and is effective for high-risk patients or recurrent cases.

    Conclusions:

    • Intracoronary stenting is a cornerstone therapy for coronary restenosis, but its benefit in small vessels requires further investigation.
    • Brachytherapy is a proven adjunctive treatment for in-stent restenosis, particularly in high-risk scenarios.
    • Emerging therapies like antiproliferative-coated stents and photoangioplasty offer future potential for restenosis management.